NASDAQ:PTIX Protagenic Therapeutics 8/14/2023 Earnings Report $3.32 -0.20 (-5.68%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.34 +0.02 (+0.45%) As of 06/13/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Protagenic Therapeutics EPS ResultsActual EPS-$3.92Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AProtagenic Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AProtagenic Therapeutics Announcement DetailsQuarterDate8/14/2023TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsProtagenic Therapeutics' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Protagenic Therapeutics Earnings HeadlinesProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comHas Trump finally met his match?Trump is making bold moves before even stepping back into the White House — securing border deals, brokering peace talks, and targeting sanctuary city funding. But according to 33-year Wall Street veteran Dylan Jovine, even Trump may not be able to fix what’s coming. Jovine believes there are five cracks forming in the U.S. economy — big enough to spark a 50% market crash, a 40% real estate plunge, and a surge in unemployment. That’s why he’s moved seven figures of his own money into a “safe haven” asset favored by names like Buffett, Musk, and Ackman. He’s released an emergency briefing explaining why the next 90 days could be critical for investors. June 15, 2025 | Behind the Markets (Ad)Protagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comSee More Protagenic Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagenic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagenic Therapeutics and other key companies, straight to your email. Email Address About Protagenic TherapeuticsProtagenic Therapeutics (NASDAQ:PTIX), a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.View Protagenic Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
